BioSpace News Archive

Drug Development

BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment

BioRestorative Therapies, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy candidate, in treating chronic lumbar disc disease (“cLDD”).

April 16, 2024
·
4 min read
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion

Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces two new studies validating the clinical benefits of blood volume analysis (BVA) as a more precise measurement of congestion in ambulatory heart failure (HF) patients.

April 16, 2024
·
3 min read
BioCapital

March of Dimes Awards Two Basil O’Connor Grants to Study Triggers of Labor Onset, Barriers to Postpartum Heart Health

March of Dimes has awarded two doctors the Basil O’Connor Starter Scholar Research Awards, the organization’s signature grants for up-and-coming scientists embarking on lifelong research paths.

April 16, 2024
·
3 min read
Pharm Country

Evergreen Theragnostics Completes $26M Capital Raise to Advance Novel Radiopharmaceutical Pipeline into the Clinic, Prepare for First Commercial Product Launch, and Expand Industry-Leading CDMO Services

Evergreen Theragnostics, Inc. today announced the successful completion of a $26M capital raise supported both by existing shareholders and new institutional investors, Petrichor and LIFTT.

April 16, 2024
·
3 min read
Business

HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2024 financial results on Tuesday, April 30, 2024, before the open of the U.S. financial markets.

April 16, 2024
·
1 min read
Pharm Country

Amneal Launches PEMRYDI RTU®, the First Ready-to-Use Version of Important Oncology Injectable Medicine

Amneal Launches PEMRYDI RTU ® , the First Ready-to-Use Version of Important Oncology Injectable Medicine.

April 16, 2024
·
6 min read
Drug Development

Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run

Nascent Biotech, Inc. announces that it is embarking on a fresh manufacturing run to ensure Pritumumab supplies are at maximum potency when patient dosing begins in the upcoming Phase II clinical trial.

April 16, 2024
·
3 min read
Pharm Country

Integral Molecular Launches Virus Neutralization Assay Services to Drive Antiviral Discovery

Integral Molecular announces the launch of its Virus Neutralization Assay Services enabling researchers to rapidly obtain high-quality data to advance their vaccines and therapeutic antibodies.

April 16, 2024
·
2 min read
Biotech Bay

Asher Bio Closes $55 Million Series C Financing to Advance Lead Program into Phase 1b Clinical Trials

Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced the closing of a Series C financing, which raised $55 million.

April 16, 2024
·
4 min read
Masimo Founder and CEO Joe Kiani to Speak on AI at Global Patient Safety Summit in Chile

Masimo announced that its Founder and CEO, Joe Kiani, will be a featured speaker tomorrow, April 17, at the 6th Global Ministerial Summit on Patient Safety.

April 16, 2024
·
8 min read